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Human biospecimens are subject to a number of different collection, processing, and storage factors that can
significantly alter their molecular composition and consistency. These biospecimen preanalytical factors, in turn,
influence experimental outcomes and the ability to reproduce scientific results. Currently, the extent and type of
information specific to the biospecimen preanalytical conditions reported in scientific publications and regula-
tory submissions varies widely. To improve the quality of research utilizing human tissues, it is critical that
information regarding the handling of biospecimens be reported in a thorough, accurate, and standardized
manner. The Biospecimen Reporting for Improved Study Quality recommendations outlined herein are intended
to apply to any study in which human biospecimens are used. The purpose of reporting these details is to supply
others, from researchers to regulators, with more consistent and standardized information to better evaluate,
interpret, compare, and reproduce the experimental results. The Biospecimen Reporting for Improved Study
Quality guidelines are proposed as an important and timely resource tool to strengthen communication and
publications around biospecimen-related research and help reassure patient contributors and the advocacy
community that the contributions are valued and respected.
Introduction
Human biospecimens provide the basis for researchleading to better understanding of human disease bi-
ology and discovery of new treatments that are tailored to
individual patients with cancer or other diseases. These bio-
logical materials are subject to a number of different collection,
processing, and storage factors that can significantly alter their
molecular composition and consistency. These preanalytical
factors, in turn, influence experimental outcomes and the
ability to reproduce scientific results.1–6 Currently, the extent
and type of information specific to the biospecimen pre-
analytical conditions reported in scientific publications and
regulatory submissions varywidely. To improve the quality of
research utilizing human tissues, it is critical that information
regarding the handling of biospecimens be reported in a
thorough, accurate, and standardized manner.
The purpose of this article was to make recommendations
for the reporting of data elements for human biospecimens,
defined as solid tissues and bodily fluids, used in biomedical
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studies. Cell lines and biospecimen derivatives such as nu-
cleic acids or proteins, although crucial for biomedical re-
search, are not intended to fall within the scope of these
recommendations. The Biospecimen Reporting for Improved
Study Quality (BRISQ) recommendations are intended to
apply to any study in which human biospecimens are used.
This includes biomedical applications such as translational
science, biomarker discovery, clinical trials, technology de-
velopment, and diagnostic-assay and therapeutics develop-
ment. The recommended data elements would be reported
by an author in a journal publication, by a company in a
regulatory submission, or by a biorepository distributing
biospecimens. It is intended that the list and the elements
within it will be interpreted, modified, and applied accord-
ing to the context of the study being reported. It is also
recognized that information corresponding to all data ele-
ments may not be available, but at least for some categories
(described below) the known or unknown status of these
elements should be documented.
The list of data elements discussed includes general in-
formation for consistent documentation of classes of bios-
pecimens and factors that might influence the integrity,
quality, and/or molecular composition of biospecimens.
Reporting the details enumerated in the BRISQ list does not
guarantee biospecimen quality and should not be seen as a
substitute for empirical quality evaluations. The purpose of
reporting these details is to supply others, from researchers
to regulatory agencies, with more consistent and standard-
ized information to better evaluate, interpret, compare, and
reproduce the experimental results. To maintain consistency
with federal regulations on research involving human sub-
jects, information that might enable individual identification
of research participants should be withheld.
The BRISQ list has been constructed as an initial step to-
ward defining reporting recommendations. The list will
likely evolve as more is learned about the factors that in-
fluence biospecimen quality and composition and, in turn,
their effects on biospecimen analysis. It is envisioned that
future iterations of the BRISQ recommendations might in-
clude changes to the list of elements and the relative weight
thereof in accordance with evidence-based scientific and
medical findings and technological developments.
Materials and Methods
A half-day workshop, Development of Biospecimen
Reporting Criteria for Publications, was held at the Na-
tional Cancer Institute (NCI) 2009 Biospecimen Research
Network Symposium (http://biospecimens.cancer.gov/
meeting/brnsymposium) to initiate a discussion on biospe-
cimen reporting recommendations. Workshop attendees in-
cluded individuals covering a broad range of expertise:
laboratory scientists, clinicians, pathologists, statisticians,
patient advocates, biobankers, journal editors, leaders of
relevant professional societies, and other stakeholders. The
attendees noted that reporting guidelines covering many as-
pects of biomedical studies already exist, particularly guide-
lines relevant to experimental design and data reporting.* It
was proposed that the BRISQ recommendations apply to all
studies utilizing human biospecimens and thus complement
existing guidelines by filling a niche concerning reporting of
biospecimen characteristics and preanalytical variables.
The attendees further proposed that the BRISQ recom-
mendations should broadly encompass solid tissues and
bodily fluids, rather than including separate lists for these
biospecimen types. It was also agreed that a committee to
develop biospecimen reporting recommendations should be
formed to take the effort forward. Many of the individuals
and disciplines participating in the workshop were included
when the BRISQ committee was subsequently formed.
Formulation of the recommendations was based on consid-
eration of what biospecimen information could enable a science
reviewer to fully evaluate or replicate a reported study. The
preliminary list included the most commonly available data
elements. The committee considered the characteristics of the
biospecimens themselves as well as numerous preanalytical
factors. Types of data elements include the tissue type and the
pathology of the sample; patient characteristics that might in-
fluence the biospecimens, such as vital and disease states; and
the collection and handling of the biospecimens, for example,
the stabilization, shipping, and storage conditions.
The preliminary list of recommendations was refined by
consulting the NCI Biospecimen Research Database (http://
brd.nci.nih.gov), an online resource compiling peer-reviewed
articles that address biospecimen science. The Biospecimen
Research Database’s terminology for scientific literature cura-
tion that was deemed relevant was incorporated into the initial
BRISQ list. This terminology served as a starting point for
discussion at monthly teleconferences by the BRISQ committee.
Results
The committee composed a list of data elements that rep-
resent factors believed to often influence biospecimen quality
and thus should be considered for reporting, if known or
applicable, for the particular study; for example, some list of
elements will be more applicable to biospecimens col-
lected for a disease-specific study than those collected for a
population-based biospecimen resource. For clarity, these
elements are organized according to the lifecycle of the bios-
pecimen (Fig. 1), which spans the period immediately prior to
removal from the patient through use in a scientific analysis.
Many reporting elements were discussed, but only some
were approved by consensus for inclusion in the guidelines.
The committee was mindful that certain information, al-
though important to report, may not have direct relevance to
the biology or condition of the biospecimen and, therefore,
would not be under the purview of the BRISQ recommen-
dations. The committee attempted to carefully balance sci-
entific interest in having access to extensive data about
biospecimen collection, processing, and storage against
practical challenges in obtaining such detailed information.
Each reporting element included in the guidelines is backed
by evidence that the factor could have an effect on the
structural integrity and molecular characteristics of the
biospecimen or on the ability to perform certain assays on
the biospecimen and obtain reliable results. Although the
committee recognizes that collection of data about biospeci-
mens can increase the operational costs to collect and
use biospecimens, cost was not factored into the exclu-
sion of data elements that were or should be considered
necessary.
*The EQUATOR project (http://www.equator-network.org/)
provides an extensive listing of guidelines for health research.
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The elements in the BRISQ list are prioritized into 3 tiers
according to the relative importance of their being reported. The
first tier, items recommended to report, includes information
such as the organ(s) or the anatomical site from which the
biospecimens were derived and the manner in which the bios-
pecimens were collected, stabilized, and preserved; for quick
reference, these items are summarized in Table 1. Reporting
these items need not be onerous. For example, Beatty et al.7
included most BRISQ Tier 1 items in the following excerpts:
 ‘‘Fine-needle aspiration specimens were obtained from
55 surgically removed specimens of breast cancer within
1 h of resection, before tissue fixation. The aspirates were
obtained using a 22- to 25-gauge needle and spread di-
rectly on slides and fixed in ethanol or formalin or
placed in CytoLyt for preparation of ThinPrep slides
according to the manufacturer’s protocol. Corresponding
formalin-fixed, paraffin-embedded tissue specimens
were fixed in 10% neutral buffered formalin for 18–24 h
according to routine procedures and embedded in
paraffin.’’
 ‘‘All fine-needle aspiration cytologic slides were air dried
and stored at room temperature before fluorescence in situ
hybridization analysis.’’
Table 1. Quick-Reference Biospecimen Reporting for Improved Study Quality Summary/Checklist:
Tier 1 Items to Report if Known and Applicable
Data elements Examples
, Biospecimen type Serum, urine
Solid tissue, whole blood, or another product derived from a human being
, Anatomical site Liver, antecubital area of the arm
Organ of origin or site of blood draw
, Disease status of patients Diabetic, healthy control
Controls or individuals with the disease of interest
, Clinical characteristics of patients Premenopausal breast cancer patients
Available medical information known or believed to be pertinent to the condition of the biospecimens
, Vital state of patients Postmortem
Alive or deceased patient when biospecimens were obtained
, Clinical diagnosis of patients Breast cancer
Patient clinical diagnoses (determined by medical history, physical examination, and analyses of the biospecimen)
pertinent to the study
, Pathology diagnosis Her2-negative intraductal carcinoma
Patient pathology diagnoses (determined by macro and/or microscopic evaluation of the biospecimen at the time
of diagnosis and/or prior to research use) pertinent to the study
, Collection mechanism Fine-needle aspiration, preoperative blood draw
How the biospecimens were obtained
, Type of stabilization Heparin, on ice
The initial process by which biospecimens were stabilized during collection
, Type of long-term preservation Formalin fixation, freezing
The process by which the biospecimens were sustained after collection
, Constitution of preservative 10% neutral-buffered formalin, 10 United States Pharmacopeia heparin units/mL
The make-up of any formulation used to maintain the biospecimens in a nonreactive state
, Storage temperature - 80C, 20C–25C
The temperature or range thereof at which the biospecimens were kept until distribution/analysis.
, Storage duration 8 days, 5–7 years
The time or range thereof between biospecimen acquisition and distribution or analysis
, Shipping temperature - 170C to - 190C
The temperature or range thereof at which biospecimens were kept during shipment or relocation
, Composition assessment and selection Minimum 80% tumor nuclei and maximum 50% necrosis
Parameters used to choose biospecimens for the study
FIG. 1. The lifecycle of the biospecimen. The preanalytical phase of the lifecycle of the biospecimen includes each stage from
patient to distribution. Preanalytical variables are addressed in the Biospecimen Reporting for Improved Study Quality list.
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Items beneficial to report form the second tier. These are
data elements an evaluator might find helpful to know but
may be slightly less crucial to the scientific contribution or
less likely to be annotated, such as the time from biospeci-
men excision/acquisition to stabilization.
Additional items to report compose the third tier. These
include information about conditions that might be useful to
know concerning the biospecimens but are not known to be
as likely to influence research results or are unlikely to be
available to researchers, such as environmental factors to
which patients were exposed or the type of storage container
in which the biospecimens were kept.
The full BRISQ list featured in Table 2 includes each item
and its definition along with additional columns that were
designed for an author or reviewer to track where the listed
items are reported for a particular study. To the right of the
Item descriptions is a column assigning each item a unique
Roman numeral/letter/number identification code. The far
right column provides space to note where each item may be
found in a manuscript or application. The far left Apply to
column indicates whether the BRISQ item is applicable to
‘‘all’’ biospecimen types or is more appropriate for solid
‘‘tissue’’ biospecimens or ‘‘fluid’’ biospecimens (such as
blood, urine, or other fluids). For example, item III.b, ‘‘Type
of long-term preservation,’’ is pertinent to all types of bios-
pecimens; item III.b.2, ‘‘Time in fixative/preservative solu-
tion,’’ is more relevant to solid tissue than to fluid
biospecimens; and item III.c, ‘‘Aliquot volume,’’ applies more
often to fluid than to solid tissue biospecimens. See the Ap-
pendix for examples of prior studies, with examples of the
effect of each BRISQ data element.
When reporting elements of the BRISQ list, standard op-
erating procedures specifying many of the pertinent details,
such as blood collection protocols, may be provided or refer-
enced; any referenced documents should be publicly available.
It is preferable that most Tier 1 items relevant to the biospe-
cimen and particular scientific study be reported directly in
the intended publication rather than be cited from another
document. Detailed descriptions that are too lengthy to be
accommodated should be made available as supplemental
materials online. Whether the laboratory performing the study
was operating under any formal certification or accreditation
should be stated if applicable to the study being reported.
The BRISQ committee discussed whether to request infor-
mation that the biorepository and/or researcher had obtained
ethical clearance to collect the biospecimens and perform the
study. Clearance from an institutional review board or similar
body is important to report in publications, and its reporting
is generally required by journals. However, it is not immedi-
ately pertinent to the structural integrity and molecular
characteristics of the biospecimen and is thus not included in
the BRISQ recommendations. Similarly, accurate biospeci-
men-tracking mechanisms are essential to biobanking but not
immediately pertinent to the condition of the biospecimen and
are thus also not included in the BRISQ data elements list.
Surgical parameters, such as type of anesthesia or receipt
of blood or other intraoperative infusates, were recognized to
be of potential significance to the condition of the biospeci-
mens. However, these data are often not known. When it is
available, information about anesthesia and intraoperative
treatments that may influence the condition of the biospeci-
mens should be reported. These elements were not included
in the BRISQ list because currently such information is rarely
available or not required to be recorded as part of biospeci-
men collection efforts. If or when surgical parameters are
determined to be critical through systematic biospecimen
research studies, these elements will be integrated into future
recommendations.
Several preservation parameters known to influence the
condition of biospecimens and the results of analyses have
been included in the list of recommendations. Researchers
should state the rationale for the chosen preservation pa-
rameters. For example, if the type and temperature of the
biospecimen preservative were selected to optimize stability,
extraction, and analysis of a particular analyte, this should be
mentioned.
The BRISQ committee recognized the need for greater
specificity in the anatomic and histologic details reported
concerning solid tissue biospecimens. The committee agreed
that the level of detail with which pathology characteristics
are reported should be enough to sufficiently address the
scientific research question. These characteristics include not
only the tissue site of the biospecimen and the relation of the
biospecimen to the pertinent clinical diagnosis within the
tissue site, but also the composition and pathology within
the biospecimen where relevant.
The BRISQ committee included members of the NCI Of-
fice of Biorepositories and Biospecimen research (OBBR),
participants from the OBBR Biospecimen Research Network
Symposium, and members of the International Society for
Biological and Environmental Repositories (ISBER) and the
committees responsible for the REporting recommendations
for tumor MARKer prognostic studies (REMARK)8 and
STrengthening the Reporting of OBservational studies in
Epidemiology (STROBE)9 guidelines. Essential harmoniza-
tion with similar efforts are underway by these groups.
Discussion
An adage in the business community states, ‘‘That which
is measured improves. That which is measured and reported
improves exponentially.’’ The BRISQ reporting recommen-
dations represent the product of extensive discussion and
input from researchers with varied types of expertise and
from many stakeholders, all of whom share the common
goal of improving biospecimen reporting and, by extension,
fields in which biospecimens are employed. The committee
believes that by providing details concerning preanalytical
factors that might affect assay results, investigators will
further improve the quality of biomedical studies, including
research for developing cancer biomarkers for screening,
early detection, and treatment.
Adoption of the BRISQ recommendations is expected to
help authors, reviewers, editors, and regulatory officials
evaluate whether sufficient information about the biospeci-
mens has been provided to enable assessment of the influence
of preanalytical biospecimen factors on study results. If re-
ported, this information will allow improved evaluation, in-
terpretation, comparison, and reproduction of the results from
studies that employ human biospecimens. Although items in
any tier might not be available or items in Tiers 2 or 3 might
not be considered significant to report, increased awareness of
their potential influence on biospecimen studies might lead to
improved tracking and reporting in the future.
The BRISQ recommendations may be implemented
by anyone reporting on studies involving biospecimens.

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Reviewers, editors, and regulatory officials might also em-
ploy the list as a tool for evaluating whether sufficient
biospecimen information has been included in a manuscript
or application. In addition, the recommendations might be
employed by investigators requesting biospecimens from a
biospecimen resource: essential items on the list might be
checked off to indicate that they are required annotation for
the desired samples. Elements of BRISQ that document
preanalytical variables for tissue biospecimens could be
economically captured using a reporting system such as the
Standard PREanalytical Code, or SPREC, which was recently
published by the ISBER Working Group on Biospecimen
Science.10
BRISQ reporting items will not be necessarily applicable
to every study, and authors and reviewers are urged to use
their judgment to decide which factors are essential. It is
not always possible for investigators to ascertain every
recommended element for every biospecimen, even for Tier
1 items, but unknown elements relevant to the study being
reported should be fully acknowledged with a discussion
of possible implications that the missing information might
have on the study conclusions. Unknown or unreported
Tier 1 data elements should not be considered a reason for
automatic dismissal of a report or conditional for the
award of a grant. The final decision on acceptability of
missing Tier 1 information should be specific to the study
context.
When consulting the BRISQ list, researchers should
evaluate the importance of each item in the context of the
study and adjust their reporting accordingly. An item such
as ‘‘method of enrichment for relevant components,’’ listed
here as Tier 2, might—for example, in the context of a study
comparing the efficacy of various enrichment methods—be
essential to report and should thus be considered Tier 1 for
that study. The converse may also be true, when, for ex-
ample, an item listed here as Tier 2—such as ‘‘temperature
between acquisition and stabilization’’—is less pertinent to
the study at hand—perhaps because the time at this tem-
perature was negligible—and should thus be considered
Tier 3.
It is hoped that consideration of the BRISQ recommen-
dations will sensitize the biobanking and research commu-
nities and their funding agencies to the importance of
tracking preanalytical variables, leading to more judicious
selection and handling of experimental human specimens
and thus improved study quality. Anecdotally, recommen-
dations such as REMARK seem to have had the effect of
spurring researchers to consider the recommendations in
advance of conducting their investigations, with the result
that researchers might take greater care in the design, con-
duct, and analysis of their studies. The BRISQ committee
envisions a similar trajectory for preanalytical biospecimen
data elements. Thus, not only might overall quality of pub-
lications improve, but the quality of human biospecimen-
dependent investigation in general might improve over time
with the formation and adoption of publication recommen-
dations. It is anticipated that biospecimen resources might
use these recommendations to improve on their existing
standard operating procedures and annotation thereof. Such
improvements could include the acquisition of additional
relevant biospecimen data based on the BRISQ recommen-
dations and the release of all such data to researchers as a
standard procedure. In this way, biospecimen resources
might become major players in the universal application of
these recommendations.
Patient contribution of biospecimens for research is a
voluntary, generous action aimed at helping advance sci-
entific discovery and progress. The research team, pathol-
ogist, and biorepository systems, as the stewards of these
biospecimens, have a responsibility to be vigilant and
persistent in using methods and practices that protect and
preserve the highest possible quality biospecimen and as-
sociated data. The BRISQ guidelines are proposed as an
important and timely resource tool to strengthen commu-
nication and publications around biospecimen-related re-
search and help reassure patient contributors and the
advocacy community that the contributions are valued and
respected. Researchers are further encouraged to strength-
en public outreach and education around the use and
potential of human biospecimens11 and the biorepository
community as these are emerging and potentially misun-
derstood areas.
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